The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness watchdog for England and Wales, has recommended Translarna (ataluren), from PTC Therapeutics (Nasdaq: PTCT), for children with Duchenne muscular dystrophy (DMD) caused by a nonsense mutation, after reaching a ‘managed access agreement’.
This agreement established financial and clinical details surrounding the use of the treatment and was a condition for making the drug available imposed by NICE in its April draft guidance.
The share price of PTC Therapeutics, a US pharma company, rose by 8% on Wednesday, when the news was announced.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze